23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › VIRIDIAN THERAPEUTICS INC. › 2023-2024

VIRIDIAN THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and VIRIDIAN THERAPEUTICS INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 163Asset managers, any item
  • 1,008Fund votes
  • June 17, 2024Meeting date

Results at a glance

Meeting of June 17, 2024: 5 items on VIRIDIAN THERAPEUTICS INC.’s Form 8-K, filed June 20, 2024: 2 elected · 3 passed (calculated).

Dissent

Significant dissent: 1 director (44.1% against); 1 say-on-pay vote (58.0% support); 1 equity or compensation plan (43.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Caligan Partners (13F, 1.9%, as of September 30, 2026) · Tang Capital (13F, 1.6%, as of September 30, 2026)

Explore VIRIDIAN THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VIRIDIAN THERAPEUTICS INC.

These tallies are VIRIDIAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VIRIDIAN THERAPEUTICS INC. — official shareholder meeting results, meeting held June 17, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Stephen Mahoney 56,413,440---- 156,1061,902,188 99.7%Elected—
Elect Director: Arlene M. Morris 31,631,097---- 24,938,4491,902,188 56%Elected—
2. Ratification of the selection of KPMG LLP as the Company's independent auditor for 2024 58,418,56931,74821,417 ---- 99.9%Passed (calculated)—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers 32,797,46823,748,21623,862 --1,902,188 58%Passed (calculated)—
4. Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares available for issuance thereunder 32,220,47424,328,88820,184 --1,902,188 57%Passed (calculated)—

Source: VIRIDIAN THERAPEUTICS INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.

How asset managers voted at the VIRIDIAN THERAPEUTICS INC. 2023-2024 meeting

163 asset managers disclosed a vote on at least one VIRIDIAN THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Arlene M. Morris

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

56% Majority: yes · of votes cast

FOR 56%WITHHELD
FOR: 31,631,097WITHHELD: 24,938,449
Details: description as filed, official tally, votes by 49 asset managers

Description as filed by funds: To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Arlene M. Morris

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Arlene M. Morris”): 31,631,097 for, 24,938,449 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 6,636,994 for, 14,033,061 withheld.

FORWITHHOLD
FOR: 6,636,994WITHHOLD: 14,033,061
Largest asset managers voting on “To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,093,2060 08,555,686Mixed
Vanguard3,062,0310 00For
State Street3,1160 02,941,945Withhold
TIAA1,251,6110 00For
AllianceBernstein00 01,014,023Withhold
BlackRock939,5180 00For
Charles Schwab00 0427,042Withhold
Principal00 0223,969Withhold
Direxion Shares ETF Trust00 0191,602Withhold
Russell Investments00 0131,754Withhold
Equitable77,5730 038,700Mixed
CARILLON SERIES TRUST00 0115,998Withhold
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares00 069,048Withhold
Nushares ETF Trust46,6650 00For
Dimensional00 038,954Withhold
Lincoln Financial00 035,700Withhold
Advisors' Inner Circle Fund III00 035,035Withhold
AIG/SunAmerica00 024,515Withhold
Northern Trust22,0080 00For
Global X00 020,792Withhold
John Hancock00 018,538Withhold
Nationwide00 017,957Withhold
Pacific Life17,5500 00For
New York Life00 016,212Withhold

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Elect Director: Stephen Mahoney

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 56,413,440WITHHELD: 156,106
Details: description as filed, official tally, votes by 49 asset managers

Description as filed by funds: To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Stephen Mahoney

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen Mahoney”): 56,413,440 for, 156,106 withheld, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 20,656,268 for, 13,787 withheld.

FOR
FOR: 20,656,268WITHHOLD: 13,787
Largest asset managers voting on “To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity9,648,8920 00For
Vanguard3,062,0310 00For
State Street2,945,0610 00For
TIAA1,251,6110 00For
AllianceBernstein1,014,0230 00For
BlackRock939,5180 00For
Charles Schwab427,0420 00For
Principal223,9690 00For
Direxion Shares ETF Trust191,6020 00For
Russell Investments131,7540 00For
Equitable116,2730 00For
CARILLON SERIES TRUST115,9980 00For
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares69,0480 00For
Nushares ETF Trust46,6650 00For
Dimensional38,9540 00For
Lincoln Financial35,7000 00For
Advisors' Inner Circle Fund III35,0350 00For
AIG/SunAmerica24,5150 00For
Northern Trust22,0080 00For
Global X20,7920 00For
John Hancock18,5380 00For
Nationwide17,9570 00For
Pacific Life17,5500 00For
New York Life16,2120 00For

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan…

Calculated outcomeFund totals may overlapCORPORATE GOVERNANCEPassed (calculated)

Combines 3 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%AGAINST
FOR: 32,220,474AGAINST: 24,328,888

Prior year: 64.9% for (June 14, 2023 meeting) ▼ 7.9 pts

Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including to increase the number of shares available for issuance thereunder.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“4. Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares available for issuance thereunder”): 32,220,474 for, 24,328,888 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 57% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 50 asset managers voting on “To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Pla” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,093,2068,555,686 00Mixed
Vanguard3,062,0310 00For
State Street3,1162,941,945 00Against
TIAA1,251,6110 00For
AllianceBernstein01,014,023 00Against
BlackRock939,5180 00For
Charles Schwab427,0420 00For
Principal164223,805 00Against
Direxion Shares ETF Trust0191,602 00Against
Russell Investments131,7540 00For
Equitable77,57338,700 00Mixed
CARILLON SERIES TRUST0115,998 00Against
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares069,048 00Against
Nushares ETF Trust46,6650 00For
Dimensional038,954 00Against
Lincoln Financial035,700 00Against
Advisors' Inner Circle Fund III035,035 00Against
AIG/SunAmerica024,515 00Against
Northern Trust022,008 00Against
Global X20,7920 00For
John Hancock018,538 00Against
Nationwide39617,561 00Against
Pacific Life17,5500 00For
New York Life16,2120 00For

Fund voting reports, all 50 managers: 7,211,881 for, 13,455,887 against, 13,787 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Pla” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Yiheng Capital Management, L.P.668,2360 00For
Kynam Capital Management, LP00 012,191Withhold

Institutional-manager reports, all 2 managers: 668,236 for, 12,191 withheld.

Approval, on an advisory basis, of the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 6 wordings of this item as funds reported it.

58% Majority: yes · of votes cast

FOR 58%AGAINST
FOR: 32,797,468AGAINST: 23,748,216

Prior year: 65.0% for (June 14, 2023 meeting) ▼ 7.0 pts

Details: description as filed, official tally, votes by 163 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 32,797,468 for, 23,748,216 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 58% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 50 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,072,2708,576,622 00Mixed
Vanguard3,062,0310 00For
State Street2,941,0334,028 00For
TIAA1,251,6110 00For
AllianceBernstein01,014,023 00Against
BlackRock0939,518 00Against
Charles Schwab0427,042 00Against
Principal0223,969 00Against
Direxion Shares ETF Trust0191,602 00Against
Russell Investments0131,754 00Against
Equitable0116,273 00Against
CARILLON SERIES TRUST0115,998 00Against
QUANTITATIVE MASTER SERIES LLC092,719 00Against
ProShares069,048 00Against
Nushares ETF Trust46,6650 00For
Dimensional038,954 00Against
Lincoln Financial35,7000 00For
Advisors' Inner Circle Fund III035,035 00Against
AIG/SunAmerica024,515 00Against
Northern Trust22,0080 00For
Global X020,792 00Against
John Hancock018,538 00Against
Nationwide017,957 00Against
Pacific Life017,550 00Against
New York Life016,212 00Against

Fund voting reports, all 50 managers: 8,476,352 for, 12,191,416 against, 13,787 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 130 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity09,377,365 00Against
Paradigm Biocapital Advisors LP04,778,003 00Against
State Street3,837,69324,170 00For
VR Adviser, LLC3,082,6700 00For
Deep Track Capital, LP3,039,3600 00For
COMMODORE CAPITAL LP1,934,6530 00For
Fairmount Funds Management LLC1,845,8130 00For
Novo Holdings A/S1,750,0000 00For
Vivo Capital, LLC1,678,2070 00For
AllianceBernstein01,516,306 00Against
BlackRock9,1271,412,506 00Against
Nuveen1,300,6110 00For
GREAT POINT PARTNERS LLC1,286,1600 00For
PERCEPTIVE ADVISORS LLC1,255,9660 00For
GEODE CAPITAL MANAGEMENT, LLC1,158,9150 00For
PICTET ASSET MANAGEMENT SA0987,650 00Against
Polar Capital Holdings Plc0882,660 00Against
5AM Venture Management, LLC736,5950 00For
Citadel727,0300 00For
Yiheng Capital Management, L.P.668,2360 00For
MPM BioImpact LLC622,0290 00For
Octagon Capital Advisors LP620,0000 00For
Charles Schwab0456,716 00Against
Northern Trust375,7751,729 00For
Candriam S.C.A.0280,000 00Against

Institutional-manager reports, all 130 managers: 26,965,627 for, 21,920,164 against, 12,191 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the selection of KPMG LLP as the Company's independent auditor for 2024

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 58,418,569AGAINST: 31,748

Prior year: 100.0% for (June 14, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 50 asset managers

Description as filed by funds: To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the selection of KPMG LLP as the Company's independent auditor for 2024”): 58,418,569 for, 31,748 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 20,667,298 for, 470 against, 13,787 abstained.

FOR
FOR: 20,667,298AGAINST: 470ABSTAIN: 13,787
Largest asset managers voting on “To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the yea” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity9,648,8920 00For
Vanguard3,062,0310 00For
State Street2,944,591470 00For
TIAA1,251,6110 00For
AllianceBernstein1,014,0230 00For
BlackRock939,5180 00For
Charles Schwab427,0420 00For
Principal223,9690 00For
Direxion Shares ETF Trust191,6020 00For
Russell Investments131,7540 00For
Equitable116,2730 00For
CARILLON SERIES TRUST115,9980 00For
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares69,0480 00For
Nushares ETF Trust46,6650 00For
Dimensional38,9540 00For
Lincoln Financial35,7000 00For
Advisors' Inner Circle Fund III35,0350 00For
AIG/SunAmerica24,5150 00For
Northern Trust22,0080 00For
Global X20,7920 00For
John Hancock18,5380 00For
Nationwide17,9570 00For
Pacific Life17,5500 00For
New York Life16,2120 00For

Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).

Largest VIRIDIAN THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 63,798,536 shares outstanding at the time of that meeting.

Fund voting reports: top VIRIDIAN THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 15.12%
2Vanguard 4.80%
3State Street 4.62%
4TIAA 1.96%
5AllianceBernstein 1.59%
6BlackRock 1.47%
7Charles Schwab 0.67%
8Principal 0.35%
9Direxion Shares ETF Trust 0.30%
10Russell Investments 0.21%
Institutional-manager reports: top VIRIDIAN THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 14.70%
2Paradigm Biocapital Advisors LP 7.49%
3State Street 6.05%
4VR Adviser, LLC 4.83%
5Deep Track Capital, LP 4.76%
6COMMODORE CAPITAL LP 3.03%
7Fairmount Funds Management LLC 2.89%
8Novo Holdings A/S 2.74%
9Vivo Capital, LLC 2.63%
10AllianceBernstein 2.38%

Reported VIRIDIAN THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

VIRIDIAN THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with Fairmount Funds Management LLC13,956,685 —Proxy statement (DEF 14A), proxy filed April 26, 2024
FMR (Fidelity)12,249,355 —Form 13F, quarter ended March 31, 2024
Entities affiliated with FMR LLC7,625,542 —Proxy statement (DEF 14A), proxy filed April 26, 2024
Entities affiliated with Venrock Healthcare Capital Partners5,555,568 —Proxy statement (DEF 14A), proxy filed April 26, 2024
BlackRock5,428,521 —Form 13F, quarter ended March 31, 2024
Entities affiliated with Deep Track Capital, LP5,378,997 —Proxy statement (DEF 14A), proxy filed April 26, 2024
Entities affiliated with Paradigm BioCapital Advisors LP5,304,313 —Proxy statement (DEF 14A), proxy filed April 26, 2024
State Street4,488,615 —Form 13F, quarter ended March 31, 2024
Vanguard Group4,331,983 —Form 13F, quarter ended March 31, 2024
Entities affiliated with Perceptive Advisors LLC4,022,066 —Proxy statement (DEF 14A), proxy filed April 26, 2024

Percentages above are of 63,798,536 shares outstanding, as reported by VIRIDIAN THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At VIRIDIAN THERAPEUTICS INC.'s shareholder meeting held June 17, 2024, in the 2023-2024 proxy season, 163 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,008 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 58% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIRIDIAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIRIDIAN THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

VIRIDIAN THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “VIRIDIAN THERAPEUTICS (VRDN) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/viridian-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.